News

Researchers found how ketamine works in depression – but that’s not all

6016 4016 Anna Stelling, PhD

Depression is a widely-spread disease, with over 264 million people being affected worldwide.1 For a subset of patients suffering from major depressive disorder (MDD), administering low doses of the anaesthetic…

read more

Malaria drug brings new hope for glioblastoma patients

4794 3196 Anna Stelling, PhD

Glioblastoma is a very aggressive form of cancer. Even though there is a low number of patients who live longer than 5 years after diagnosis – a statistic that researchers…

read more

Does COVID-19 affect the brain?

1920 1080 Anne Carter, MA (Cantab)

With EAN going virtual this year, the global SARS-CoV2 pandemic was never far from the attendees’ minds. After a brief overview of the putative mechanisms for SARS-CoV2 accessing the brain,…

read more
Brain, Man, Alzheimers

Optimising early diagnosis of Alzheimer’s disease – mission impossible?

1920 1080 Anna Stelling, PhD

Alzheimer’s disease (AD) is a very common malady of the elderly, currently affecting 5.8 million Americans above the age of 65. It accounts for 60–80% of all dementia cases, which…

read more
Sun, ray of light, forest, trees

Siponimod shows promising long-term efficacy in SPMS patients

1920 1280 Anna Stelling, PhD

While researchers are looking at the potential of stem cells in the treatment of multiple sclerosis (MS), novel, promising immune-modulating therapies are being developed. At this year’s virtual EAN Congress,…

read more

Paediatric multiple sclerosis: Adding to our knowledge

1920 1080 Anne Carter, MA (Cantab)

Data suggest that between 2 and 5% of patients with multiple sclerosis (MS) are under 18 years old,1 yet there is only one approved treatment option in this population.2,3 During…

read more
Elderly man on bench by himself outdoors

Why do some glioblastoma patients live longer than others?

1920 1280 Anna Stelling, PhD

Why do some glioblastoma patients live longer than others? Alice Laurenge (Institut du Cerveau et de la Moelle épinière, Sorbonne Université and Hôspitaux universitaire La Pitié Salpêtrière – Charles Foix,…

read more

How to choose antiepileptic drug treatment for refractory epilepsy?

1920 1280 Anne Carter, MA (Cantab)

While most patients with epilepsy respond to one or two drugs, it is estimated that 30% develop drug resistance.1 At EAN 2020, Sylvain Rheims (Department of Functional Neurology and Epileptology,…

read more

Why B-cell therapies, or why not?

3848 2300 Peter Stevenson, PhD

The rational for B-cell therapy in multiple sclerosis (MS) was presented during ECTRIMS 2019, with David Baker (Blizard Institute, Queen Mary University of London, UK) posing the question of why…

read more

Are stem cells in MS ready for prime time?

2300 1535 Peter Stevenson, PhD

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

read more
Brainwork is supported by unrestricted grants from: